ENERGENESIS
華安醫學股份有限公司
ENERGENESIS is a Taiwan TWSE-listed biotechnology company; its most advanced asset is ENERGI-F703 GEL (Phase 3; recruiting, Diabetic Foot Ulcer; Foot Ulcer; Diabetes Mellitus; Wound), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ENERGI-F703 GEL | — | Phase 3; recruiting | Diabetic Foot Ulcer; Foot Ulcer; Diabetes Mellitus; Wound | Taiwan, United States | 2025-10-02 | Trial registry |
| ENERGI-F703EB | — | Phase 2; recruiting | Epidermolysis Bullosa (EB); Junctional Epidermolysis Bullosa; Epidermolysis Bullosa Simplex; Dystrophic Epidermolysis Bullosa | Taiwan | 2026-10-05 | Trial registry |
| ENERGI-F701 | — | Phase 2; completed | Female Pattern Baldness; Hair Loss; Alopecia | Taiwan | 2020-11-24 | Trial registry |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.